Apr 17, 2017 - Despite a climbing market, these stocks fell. Find out why.
Apr 17, 2017 - 2017 is expected to be a strong year for drug stocks.
Apr 17, 2017 - Shares of Incyte and Eli Lilly are reeling following the FDA's rejection of their once-daily rheumatoid arthritis pill.
Apr 17, 2017 - Names on the move ahead of the open.
Apr 17, 2017 - Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.
Apr 17, 2017 - Zoetis Inc. (ZTS) announced an agreement to buy Nexvet Biopharma plc (NVET) for an aggregate equity valuation of approximately $85 million
Apr 17, 2017 - IDEX Corporation (IEX) is scheduled to report first-quarter 2017 results after the closing bell on Apr 19.
Apr 17, 2017 - Wall Street's fear gauge is breaking out higher as geopolitical risks heat up after the U.S. opted for 'Mother of All Bombs'.
Apr 14, 2017 - Eli Lilly and Incyte said the U.S. Food and Drug Administration didn’t approve their new drug application for a rheumatoid arthritis treatment that some analysts estimate could generate more than $2 billion in annual sales.
Apr 14, 2017 - A Lilly-Incyte rheumatoid arthritis drug won’t come to market any time soon after the FDA’s surprise rejection of the treatment.